Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Return on Sales (2021 - 2025)

Historic Return on Sales for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 0.11%.

  • Tarsus Pharmaceuticals' Return on Sales rose 3800.0% to 0.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.22%, marking a year-over-year increase of 8000.0%. This contributed to the annual value of 0.63% for FY2024, which is 71600.0% up from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Return on Sales is 0.11%, which was up 3800.0% from 0.2% recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Return on Sales peaked at 0.33% during Q2 2021, and registered a low of 42.87% during Q4 2021.
  • For the 5-year period, Tarsus Pharmaceuticals' Return on Sales averaged around 7.43%, with its median value being 1.29% (2024).
  • Over the last 5 years, Tarsus Pharmaceuticals' Return on Sales had its largest YoY gain of 415100bps in 2022, and its largest YoY loss of -371200bps in 2022.
  • Over the past 5 years, Tarsus Pharmaceuticals' Return on Sales (Quarter) stood at 42.87% in 2021, then skyrocketed by 97bps to 1.36% in 2022, then tumbled by -138bps to 3.25% in 2023, then surged by 89bps to 0.35% in 2024, then skyrocketed by 69bps to 0.11% in 2025.
  • Its Return on Sales stands at 0.11% for Q3 2025, versus 0.2% for Q2 2025 and 0.32% for Q1 2025.